Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | GCGR | P47871 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MITF | O75030 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.44 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | FEN1 | P39748 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | RAF1 | P04049 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410945 | 0.83 | RAB9A (0.56) | PTGS2ALDH1A1SMN1; SMN2KDM4EMITF | |
| SCHEMBL5941146 | 0.81 | ALOX5AP (0.40) | PTGS2KDM4EMITFLMNASTAT3 | |
| SCHEMBL5850352 | 0.77 | MAPK14 (0.53) | PTGS2MAPK14GCGRALDH1A1SMN1; SMN2 | |
| SCHEMBL5850146 | 0.77 | MAPK14 (0.49) | PTGS2MAPK14GCGRMAPK11MAPK13 | |
| SCHEMBL6633321 | 0.76 | MAPK14 (0.51) | PTGS2MAPK14ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3135636 | 0.76 | SCN9A (0.54) | ALDH1A1SMN1; SMN2KDM4EMITFLMNA | |
| SCHEMBL1554769 | 0.73 | BRAF (0.46) | PTGS2MAPK14PTGS1MAPK9CSNK1A1 | |
| SCHEMBL7971869 | 0.73 | PTGS2 (1.00) | PTGS2MAPK14GCGRMAPK11MAPK13 | |
| SCHEMBL10733900 | 0.73 | PTGS2 (1.00) | PTGS2MAPK14GCGRMAPK11MAPK13 | |
| SCHEMBL4977359 | 0.72 | MAPK14 (0.56) | MAPK14GCGRALDH1A1SMN1; SMN2MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1294129-C | Heteraryl-substituted porrole derivatives, their prep. and therapeutic use | SANKYO CO (JP) | 2007-01-10 | — | — | CN | disclosed |
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| CN-1525968-A | composition for preventing or treating liver disease | 三共株式会社 | 2004-09-01 | — | — | CN | disclosed |
| EP-1070711-B1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO CO (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1243589-A1 | Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2002-09-25 | — | — | EP | disclosed |
| CN-1295069-A | Heteraryl-substituted porrole derivatives, their prep. and therapeutic use | SANKYO CO (JP) | 2001-05-16 | — | — | CN | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | PTGS2 119/4885MAPK14 3902/4885GCGR 3466/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | PTGS2 116/4885MAPK14 4157/4885GCGR 2716/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | PTGS2 88/4885MAPK14 3593/4885GCGR 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.